Catalog No.
PHJ98001
Species reactivity
Human, Mouse, Rat
Host species
Rabbit
Isotype
IgG
Clonality
Polyclonal
Immunogen
E. coli - derived recombinant Human SCG3 (Phe20-Leu468).
Tested applications
ELISA: 1:4000-1:8000, IHC: 1:50-1:100, WB: 1:1000-1:4000
Target
SgIII, Secretogranin-3, SCG3, Secretogranin III
Purification
Purified by antigen affinity column.
Accession
Q8WXD2
Applications
ELISA, IHC, WB
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Note
For research use only.
Cetuximab plus radiotherapy for the treatment of locally advanced squamous cell carcinoma of the head and neck., PMID:19567214
Secretogranin III as a disease-associated ligand for antiangiogenic therapy of diabetic retinopathy., PMID:28330905
Secretogranin III: a diabetic retinopathy-selective angiogenic factor., PMID:28856381
Secretogranin III promotes angiogenesis through MEK/ERK signaling pathway., PMID:29154827
Secretogranin III as a novel target for the therapy of choroidal neovascularization., PMID:30633921
Anti-secretogranin III therapy of oxygen-induced retinopathy with optimal safety., PMID:30644010
TRPV1, TRPA1, and TRPM8 are expressed in axon terminals in the cornea: TRPV1 axons contain CGRP and secretogranin II; TRPA1 axons contain secretogranin 3., PMID:38860239
TRPV1, TRPA1, and TRPM8 are expressed in axon terminals in the cornea: TRPV1 axons contain CGRP and secretogranin II; TRPA1 axons contain secretogranin 3., PMID:32863706
Novel Insight in Idiopathic Normal Pressure Hydrocephalus (iNPH) Biomarker Discovery in CSF., PMID:34360799
Selectively targeting disease-restricted secretogranin III to alleviate choroidal neovascularization., PMID:34918375
Secretogranin III stringently regulates pathological but not physiological angiogenesis in oxygen-induced retinopathy., PMID:35006382
Optimal Efficacy and Safety of Humanized Anti-Scg3 Antibody to Alleviate Oxygen-Induced Retinopathy., PMID:35008775
Comparative ligandomics implicates secretogranin III as a disease-restricted angiogenic factor in laser-induced choroidal neovascularization., PMID:35038348
Safety and Efficacy of Systemic Anti-Scg3 Therapy to Treat Oxygen-Induced Retinopathy., PMID:35468689
Inhibitory effect of anti-Scg3 on corneal neovascularization: a preliminary study., PMID:36443679
Secretogranin III Selectively Promotes Vascular Leakage in the Deep Vascular Plexus of Diabetic Retinopathy., PMID:37445707
Anti-Scg3 Gene Therapy to Treat Choroidal Neovascularization in Mice., PMID:37509549
Large-scale phenotyping of patients with long COVID post-hospitalization reveals mechanistic subtypes of disease., PMID:38589621
Optimal Humanized Scg3-Neutralizing Antibodies for Anti-Angiogenic Therapy of Diabetic Retinopathy., PMID:39273454
Suppression of matrigel-induced choroidal neovascularization by AAV delivery of a novel anti-Scg3 antibody., PMID:39333408
For research use only. Not for human or drug use.
